| pubmed-article:17804227 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17804227 | lifeskim:mentions | umls-concept:C1152564 | lld:lifeskim |
| pubmed-article:17804227 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:17804227 | lifeskim:mentions | umls-concept:C2698650 | lld:lifeskim |
| pubmed-article:17804227 | lifeskim:mentions | umls-concept:C0216510 | lld:lifeskim |
| pubmed-article:17804227 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:17804227 | pubmed:dateCreated | 2007-10-1 | lld:pubmed |
| pubmed-article:17804227 | pubmed:abstractText | The development of 2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-ones as inhibitors of Chk1 kinase is described. Introduction of a fused ring at the C7/C8 positions of the pyrazoloquinolinone provided an increase in potency while guidance from overlapping inhibitor bound Chk1 X-ray crystal structures contributed to the discovery of a potent and solubilizing propyl amine moiety in compound 52 (Chk1 IC(50)=3.1 nM). | lld:pubmed |
| pubmed-article:17804227 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17804227 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17804227 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17804227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17804227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17804227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17804227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17804227 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17804227 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17804227 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:HartmanGeorge... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:KuoLawrence... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:RickertKeithK | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:WalshEileen... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:LobellRobert... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:BuserCarolyn... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:FraleyMark... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:StirdivantSte... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:Sepp-Lorenzin... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:ArringtonKenn... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:HamiltonKelly... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:YanYouweiY | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:DudkinVadim... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:GarbaccioRobe... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:MaoXianzhiX | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:TasberEdward... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:KreatsoulasCo... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:MunshiSanjeev... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:TaoWeikangW | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:IkutaMariM | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:HardwickJames... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:SteenJustin... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:BrnardicEdwar... | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:DrakasBob ABA | lld:pubmed |
| pubmed-article:17804227 | pubmed:author | pubmed-author:BeckStephen... | lld:pubmed |
| pubmed-article:17804227 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17804227 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:17804227 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:17804227 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17804227 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17804227 | pubmed:pagination | 5989-94 | lld:pubmed |
| pubmed-article:17804227 | pubmed:dateRevised | 2011-11-2 | lld:pubmed |
| pubmed-article:17804227 | pubmed:meshHeading | pubmed-meshheading:17804227... | lld:pubmed |
| pubmed-article:17804227 | pubmed:meshHeading | pubmed-meshheading:17804227... | lld:pubmed |
| pubmed-article:17804227 | pubmed:meshHeading | pubmed-meshheading:17804227... | lld:pubmed |
| pubmed-article:17804227 | pubmed:meshHeading | pubmed-meshheading:17804227... | lld:pubmed |
| pubmed-article:17804227 | pubmed:meshHeading | pubmed-meshheading:17804227... | lld:pubmed |
| pubmed-article:17804227 | pubmed:meshHeading | pubmed-meshheading:17804227... | lld:pubmed |
| pubmed-article:17804227 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17804227 | pubmed:articleTitle | Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors. | lld:pubmed |
| pubmed-article:17804227 | pubmed:affiliation | Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. edward_brnardic@merck.com | lld:pubmed |
| pubmed-article:17804227 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17804227 | lld:chembl |
